Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of LY2835219 in Healthy Subjects
NCT02327143Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration-Time Curve From Zero to Infinity. Started Jan 2015; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02327143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327143.